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Inducible prostaglandin synthase (cyclooxygenase-2, COX-2) is expressed in rheumatoid and osteoarthritic cartilage and produces
high amounts of proinflammatory prostanoids in the joint. In the present study we investigated the eﬀects of the inhibitors of
mitogen-activated protein kinase (MAPK) pathways Erk1/2, p38, and JNK on COX-2 expression and prostaglandin E2 (PGE2)
production in human chondrocytes. Proinflammatory cytokine IL-1β caused a transient activation of Erk1/2, p38, and JNK in im-
mortalized human T/C28a2 chondrocytes and that was followed by enhanced COX-2 expression and PGE2 production. PD98059
(an inhibitor of Erk1/2 pathway) suppressed IL-1-induced COX-2 expression and PGE2 production in a dose-dependent manner,
and seemed to have an inhibitory eﬀect on COX-2 activity. SB203580 (an inhibitor of p38 pathway) but not its negative control
compound SB202474 inhibited COX-2 protein and mRNA expression and subsequent PGE2 synthesis at micromolar drug concen-
trations. SP600125 (a recently developed JNK inhibitor) but not its negative control compound N1-methyl-1,9-pyrazolanthrone
downregulated COX-2 expression and PGE2 formation in a dose-dependent manner. SP600125 did not downregulate IL-1-induced
COX-2 mRNA expression when measured 2 h after addition of IL-1β but suppressed mRNA levels in the later time points suggest-
ing post-transcriptional regulation. Our results suggest that activation of Erk1/2, p38, and JNK pathways belongs to the signaling
cascades that mediate the upregulation of COX-2 expression and PGE2 production in human chondrocytes exposed to proinflam-
matory cytokine IL-1β.
INTRODUCTION
Prostaglandins (PGs) are present in a wide variety
of human tissues, where they regulate physiological re-
sponses, including vascular tone, blood clotting, kid-
ney function, gastric secretion and reproduction [1]. In
arthritis, prostaglandins (especially PGE2) are produced
inmuch higher amounts, and theymediate inflammation,
tissue destruction, and inflammatory pain. PGs are syn-
thesized from arachidonic acid by cyclooxygenase (COX)
enzymes [2, 3]. Two isoforms of COX have been identi-
fied: COX-1 is constitutively expressed and produces low
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physiological levels of prostanoids, whereas the expression
of the inducible isoform, COX-2, is increased in response
to proinflammatory cytokines or bacterial products [4].
COX-2 is highly expressed in rheumatoid (RA) and os-
teoarthritic (OA) cartilage [5, 6]. Interleukin (IL)-1 is a
key cytokine involved in the joint destruction in RA and
OA and it has been shown to enhance COX-2 expression
in articular chondrocytes [5, 7, 8].
Mitogen-activated protein kinases (MAPKs) are a
family of serine/threonine kinases, that are part of the sig-
nal transduction pathways which connect inflammatory
and other extracellular signals to intracellular responses,
for example, gene expression. The three better character-
izedMAPK pathways are extracellular signal-regulated ki-
nase 1 and 2 (Erk1/2), p38, and c-Jun N-terminal kinase
(JNK). The growth-factor-induced Erk1/2, and the stress-
activated p38 and JNK protein kinases are phosphorylated
in response to extracellular stimuli at conserved threo-
nine and tyrosine residues and have regulatory functions
in inflammation [9, 10]. Inhibitors of p38 and JNK are
under development for treatment of arthritis and they
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have shown eﬃcacy in experimentally induced arthritis
and joint pain [11, 12]. Inhibition of MAPKs is likely to
result in suppression of inflammatorymediators, which in
turn leads to the desired therapeutic eﬀects. We hypothe-
sized that one of the inflammatory pathways in the carti-
lage, that might be down-regulated by MAPK inhibitors,
is COX-2-PGE2 pathway. The aim of the present study
was to investigate if inhibitors of JNK (SP600125), p38
(SB203580), and Erk1/2 (PD98059) MAP-kinase path-
ways downregulate IL-induced COX-2 expression and
PGE2 production in human chondrocytes.
MATERIALS ANDMETHODS
Materials
Reagents were obtained as follows: SP600125
(anthra[1,9-cd]pyrazol-6(2H)-one), SB203580 (4-(4-
fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-
imidazole), and PD98059 (2-(2′-amino-3′-methoxy-
phenyl)-oxanaphthalen-4-one) were from Calbiochem
(La Jolla, Calif); goat polyclonal human COX-2, rabbit
polyclonal JNK, donkey anti-goat polyclonal, and goat
anti-rabbit polyclonal antibodies were from Santa Cruz
Biotechnology, Inc, (Santa Cruz, Calif); and rabbit
polyclonal phospho-JNK, phospho-Erk1/2, Erk1/2,
phospho-p38, and p38 antibodies were from Cell Signal-
ing Technology, Inc, (Beverly, Mass). All other reagents
were from Sigma Chemical Co (St Louis, Mo).
Cell culture
Immortalized human T/C28a2 chondrocytes [13]
were grown in Dulbecco’s modified Eagle’s medium
(Cambrex Bioproducts Europe, Verviers, Belgium) and
Ham’s F-12 medium (Gibco, Paisley, Scotland) (1:1,
v/v). Culture media contained 10% heat-inactivated fe-
tal bovine serum, 100U/mL penicillin, 100 µg/mL strep-
tomycin, and 250 ng/mL amphotericin B (all from Gibco,
Paisley, Scotland). Cells were seeded on 24-well plates
for prostaglandin E2 measurements and on 6-well plates
for Western blot and RT-PCR. Cell monolayers were
grown for 72 h to confluence before the experiments were
started and the compounds of interest were added in fresh
medium.
Prostaglandin E2 assays
At the indicated time points, the culture medium
was collected for prostaglandin E2 (PGE2) measure-
ment. PGE2 concentrations were determined by radioim-
munoassay using reagents from the Institute of Isotopes
(Budapest, Hungary).
Western blot analysis
At the indicated time points, cells were rapidly washed
with ice-cold PBS and solubilized in cold lysis buﬀer con-
taining 10mM Tris base, 5mM EDTA, 50mM NaCl, 1%
Triton X-100, 0.5mM phenylmethylsulfonyl fluoride,
2mM sodium orthovanadate, 10 µg/mL leupeptin,
25 µg/mL aprotinin, 1.25mM NaF, 1mM sodium py-
rophosphate, and 10mM n-octyl-β-D-glucopyranoside.
After incubation for 20min on ice, lysates were cen-
trifuged (14 500 g for 10min), and supernatants were
mixed in a ratio of 1:4 with SDS loading buﬀer (62.5mM
Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 0.025% bro-
mophenol blue, and 5% β-mercaptoethanol) and boiled
for 5min. Protein concentrations in the samples were
measured by the Coomassie blue method [14]. After
boiling for 5min, equal aliquots of protein (20 µg) were
loaded on a 10% SDS-polyacrylamide electrophoresis gel
and electrophoresed for 4 h at 100V in a buﬀer containing
95mM Tris-HCl, 960mM glycine, and 0.5% SDS. After
electrophoresis, the proteins were transferred to Hybond-
enhanced chemiluminescence nitrocellulose membrane
(Amersham, Buckinghamshire, UK) with semidry blotter
at 2.5mA/cm2 for 60min. After transfer, the membrane
was blocked in TBS/T (20mM Tris-base pH 7.6, 150mM
NaCl, 0.1% Tween-20) containing 5% nonfat milk for
1 h at room temperature and incubated overnight at
4◦C with COX-2, JNK, p38, Erk1/2, phospho-specific
JNK, phospho-specific p38, or phospho-specific Erk1/2
antibodies in TBS/T containing 5% nonfat milk. There-
after the membrane was washed 4 times with TBS/T
for 5min, incubated with secondary antibody coupled
to horseradish peroxidase in the blocking solution for
0.5 h at room temperature, and washed four times with
TBS/T for 5min. Bound antibody was detected using
SuperSignal West Pico chemiluminescent substrate
(Pierce, Cheshire, UK) and FluorChem 8800 imaging
system (Alpha Innotech Corp, San Leandro, Calif). The
quantitation of the chemiluminescent signal was carried
out with the use of FluorChem software version 3.1.
RNA extraction and real-time RT-PCR
At the indicated time points, cell monolayers were
rapidly washed with ice-cold PBS, and cells were ho-
mogenized using QIAshredder (QIAGEN, Valencia,
Calif). RNA extraction was carried out with the use of
RNeasy kit for isolation of total RNA (QIAGEN). Total
RNA (25 ng) was reverse-transcribed to cDNA using
TaqMan reverse transcription reagents and random
hexamers (Applied Biosystems, Foster City, Calif). cDNA
obtained from the RT reaction (amount corresponding
to approximately 1 ng of total RNA) was subjected to
PCR using TaqMan Universal PCR Master Mix and
ABI PRISM 7000 Sequence detection system (Applied
Biosystems). The primer and probe sequences and
concentrations were optimized according to manufac-
turer’s guidelines in TaqMan Universal PCR Master Mix
Protocol part number 4304449 revision C and they were
5′ - CAACTCTATATTGCTGGAACATGGA - 3′ (human
COX-2 forward primer, 300 nM), 5′-TGGAAGCCTGT-
GATACTTTCTGTACT-3′ (human COX-2 reverse primer,
300 nM), 5′-TCCTACCACCAGCAACCCTGCCA-3′ (hu-
man COX-2 probe containing 6-FAM as 5′-reporter dye
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Figure 1. The eﬀects of IL-1β on JNK, p38, and Erk1/2 MAPK
activation in human T/C28a2 chondrocytes. The chondrocytes
were stimulated with IL-1β (100 pg/mL). Incubations were ter-
minated at the indicated time points. Two parallel immunoblots
were run from same cell lysates using antibodies against the Thr-
183/Tyr-185, Thr-180/Tyr-182, and Thr-202/Tyr-204 phospho-
rylated (ie, activated) JNK (p-JNK), p38 (p-p38), and Erk1/2 (p-
Erk1/2) and against total JNK, p38, and Erk1/2. The experiment
was repeated three times with similar results.
and TAMRA as 3′-quencher, 150 nM). Human β-actin
was obtained from TaqMan Human β-actin Reagents kit
(Applied Biosystems), containing VIC as 5′-reporter dye
and TAMRA as 3′-quencher. PCR reaction parameters
were as follows: incubation at 50◦C for 2min, incubation
at 95◦C for 10min, and thereafter 40 cycles of denatura-
tion at 95◦C for 15 s and annealing and extension at 60◦C
for 1min. Each sample was determined in duplicate.
A standard curve method was used to determine the
relative mRNA levels as described in the Applied Biosys-
tems User Bulletin: a standard curve for each gene was
created using RNA isolated from IL-1β-stimulated hu-
man T/C28a2 chondrocytes. Isolated RNA was reverse-
transcribed and dilution series of cDNA ranging from 1 pg
to 10 ng were subjected to real-time PCR. The obtained
threshold cycle values were plotted against the dilution
factor to create a standard curve. Relative mRNA levels in
test samples were then calculated from the standard curve.
Statistics
Results are expressed as the mean ± SEM. Statistical
significances were calculated by analyses of variance sup-
ported by the Dunnett’s multiple comparisons test. Dif-
ferences were considered significant at P < .05.
RESULTS
IL-1β-activated JNK, p38, and Erk1/2 in human
T/C28a2 chondrocytes
The ability of IL-1β to activate JNK, p38, and Erk1/2
pathways was studied by Western blot analysis using an-
tibodies directed against Thr-183/Tyr-185, Thr-180/Tyr-
182, and Thr-202/Tyr-204 phosphorylated (ie, activated)
JNK, p38, and Erk1/2, respectively. JNK activation was
seen 20min after addition of IL-1β. The activation peaked
at 1 hour and decreased thereafter. The activation of p38
and Erk1/2 was detected 3–6min after addition of IL-1β,
peaked at 10–20min, and declined after 1 hour (Figure 1).
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Figure 2. The eﬀects of IL-1β on COX-2 protein expression and
PGE2 production in human T/C28a2 chondrocytes. (a) Human
chondrocytes were incubated for 24 h in the presence of increas-
ing concentrations of IL-1β, and COX-2 protein was measured
by Western blot. (b) Human chondrocytes were incubated for
24 h in the presence of increasing concentrations of IL-1β, and
PGE2 concentrations in the culture medium were measured by
radioimmunoassay. COX inhibitor ibuprofen (10 µM) was used
as a control compound. Mean ± SEM, n = 4− 6. In (a), a repre-
sentative gel is shown under the bars.
IL-1β-induced COX-2 expression and PGE2 production
in human T/C28a2 chondrocytes
IL-1β enhanced COX-2 expression in a concentration-
dependent manner, being detectable at 10 pg/mL and in-
creasing up to 1000 pg/mL (Figure 2a). Radioimmunoas-
say of prostaglandin E2 (PGE2) in the culturemediumwas
carried out to investigate PGE2 production. IL-1β induced
PGE2 production in a concentration-dependent manner.
Increased PGE2 production was detected at 10 pg/mL of
IL-1β and was maximal at 100 pg/mL remaining elevated
up to 1000 pg/mL (Figure 2b).
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SP600125, SB203580, and PD98059 suppressed
IL-1β-induced PGE2 production in human
T/C28a2 chondrocytes
Inhibitors of JNK (SP600125), p38 (SB203580), and
Erk1/2 (PD98059) reduced IL-1β-induced PGE2 pro-
duction in T/C28a2 chondrocytes in a concentration-
dependent manner (Figures 3a, 3b, 3c). In the further
studies, SP600125, SB203580, and PD98059 were added
in T/C28a2 chondrocyte cultures at the same time or 6 h
after IL-1β. In contrast to the inhibitory eﬀect seen when
added at the same time, SP600125 (10 µM) and SB203580
(1 µM) did not inhibit PGE2 production when added 6 h
after IL-1β. PD98059 (10 µM) inhibited the production of
PGE2 also when added 6 h after IL-1β, but the inhibition
was notably less than when added to cells at the same time
as the stimulus (Figure 3g).
SP600125, SB203580, and PD98059 inhibited COX-2
expression in human T/C28a2 chondrocytes
In the further studies, we measured the eﬀects of
SP600125, SB203580, and PD98059 on IL-1β-induced
COX-2 protein expression. Western blots using antibody
against COX-2 showed that the three inhibitors caused
a concentration-dependent reduction in IL-1β-induced
COX-2 protein levels (Figures 3b, 3d, 3f). Negative control
compounds were available for SP600125 and SB203580
and their eﬀects on COX-2 expression were also tested.
N1-methyl-substituted pyrazolanthrone is structurally re-
lated to SP600125 but it is over 100-fold less potent
inhibitor of JNK than SP600125 [15]. N1-methyl-1,9-
pyrazolanthrone (10 µM) had no eﬀect on COX-2 expres-
sion while SP600125 (10 µM) reduced COX-2 expression
by 70%. SB202474 is structurally related to SB203580 but
does not inhibit p38 [16]. SB202474 (1 µM) did not sup-
press COX-2 expression while SB203580 (1 µM) inhibited
COX-2 expression by 40%.
SP600125, SB203580, and PD98059 inhibited COX-2
mRNA expression in human T/C28a2 chondrocytes
We used real-time RT-PCR to investigate the eﬀects of
SP600125, SB203580, and PD98059 on COX-2 mRNA ex-
pression. IL-1β induced transient COX-2 expression that
peaked 4 h after addition of IL-1. SB203580 and PD98059
reduced IL-1β-induced COX-2 mRNA expression signif-
icantly when measured either 2 h or 8 h after IL-1β stim-
ulation. In contrast, SP600125 had no marked eﬀect on
IL-1β-induced COX-2 mRNA expression at the 2 h time
point, whereas the level of COX-2 mRNA was reduced by
about 75% at the 8 h time point (Figure 4).
DISCUSSION
In the present study, we found that inhibitors of JNK,
p38, and Erk1/2 pathways downregulate IL-1-induced
COX-2 expression and PGE2 production in human chon-
drocytes.
Consistently with earlier findings using primary ar-
ticular chondrocytes [17, 18], our results show that IL-
1β causes a rapid activation of JNK, p38, and Erk1/2
MAP kinases in immortalized human T/C28a2 chondro-
cytes. These events were followed by enhanced COX-2
expression and subsequent PGE2 production. Inhibition
of JNK activity by SP600125, p38 activity by SB203580,
and Erk1/2 activity by PD98059 resulted in a reduc-
tion in the amount of PGE2 produced. However, when
SP600125 and SB203580 were added 6 h after IL-1β, they
did not aﬀect PGE2 production. These findings suggest
that SP600125 and SB203580 did not inhibit COX-2 activ-
ity, but rather reduced the expression of COX-2. PD98059
inhibited the production of PGE2 also when added 6 h
after IL-1β, but the inhibition was notably smaller than
in those experiments where PD98059 was added at the
same time as IL-1β. This suggests that PD98059 may
have also some inhibitory eﬀect on cyclooxygenase ac-
tivity in activated chondrocytes, as has been earlier re-
ported in arachidonic-acid-stimulated human platelets
[19]. Western blot analysis showed that all the three in-
hibitors (SP600125, SB203580, and PD98059) caused also
a concentration-dependent reduction in COX-2 protein
levels in IL-1-treated chondrocytes.
In the real-time RT-PCR studies, SP600125 had prac-
tically no eﬀect on IL-1β-induced COX-2 mRNA expres-
sion in human T/C28a2 chondrocytes when measured 2 h
after IL-1β, whereas when measured 8 h after the addition
of IL-1β, a significant reduction in the levels of COX-2
mRNA was observed in the presence of SP600125. These
results suggest that inhibition of JNK pathway does not
aﬀect the early events in IL-1-induced COX-2 expression
but it may regulate the process at post-transcriptional
level.
SB203580 and PD98059 had a significant eﬀect on
COX-2 mRNA expression when measured 2 h after ad-
dition of IL-1β. Our results are consistent with previous
reports showing that p38 and Erk1/2 MAP kinase path-
ways are involved in the cellular events leading to upregu-
lation of COX-2 gene transcription in human monocytes
and in RAW264 macrophages [20, 21, 22, 23, 24]. In ad-
dition, p38 has also reported to stabilize COX-2 mRNA in
mammary carcinoma cells, in HeLa-TO cells, and another
chondrocyte cell line [25, 26, 27].
We have earlier shown that, in J774 macrophages,
SP600125, SB203580, and PD98059 do not have an eﬀect
on nuclear translocation and DNA binding activity of NF-
κB [28, 29, 30] which plays a role in stimulating COX-2
expression [31]. In addition to NF-κB, the expression of
COX-2 is regulated by other factors including NF-IL6 and
AP-2 [32, 33]. Further studies are needed to determine the
molecular mechanisms which mediate the eﬀects of JNK,
p38, and Erk1/2 inhibitors on COX-2 expression.
Inhibitors of p38 and JNK are under development
for treatment of arthritis and they have been shown
to have antiinflammatory and antierosive eﬀects in ex-
perimentally induced arthritis, and to relief inflamma-
tory pain [10, 11]. The inhibition of MAP kinases and
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Figure 3. The eﬀects of SP600125, SB203580, and PD98059 on PGE2 production and COX-2 protein expression in IL-1β-stimulated
human T/C28a2 chondrocytes. Human chondrocytes were incubated with IL-1β (100 pg/mL) and increasing concentrations of (a),
(b) SP600125 (JNK inhibitor), (c), (d) SB203580 (p38 inhibitor), and (e), (f) PD98059 (Erk1/2 inhibitor). After 24 h, incubations were
terminated, and PGE2 concentrations in the culture medium were measured by RIA ((a), (c), (e)) and COX-2 protein was measured
by Western blot ((b), (d), (f)). (g) SP600125 (10 µM), SB203580 (1 µM), and PD98059 (10 µM) were added to the cell culture at the
same time (0 h) or 6 h after IL-1β (6 h). After 24 h, PGE2 concentrations were measured in the culture medium by RIA. Mean ± SEM,
n = 4, ∗∗ indicates P < .01 as compared with the respective control. In (b), (d), and (f) a representative gel is shown under the bars.
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Figure 4. The eﬀects of SP600125, SB203580, and PD98059 on
COX-2 mRNA levels in IL-1β-stimulated human chondrocytes.
Human chondrocytes were incubated with IL-1β (100 pg/ml)
and with or without SP600125, SB203580, and PD98059. Incu-
bations were terminated at the indicated time points, and the
extracted total RNA was subjected to real-time RT-PCR. COX-2
mRNA levels were normalized against β-actin mRNA. Mean ±
SEM, n = 6,∗∗ indicates P < .01 as compared with cells treated
with IL-1β only.
subsequent inhibition of the synthesis of a number of
important proinflammatory cytokines like IL-1, TNF-α,
IL-6, IL-8, and matrix metalloproteases has been identi-
fied as a mechanism contributing to the antiinflammatory
activity of these compounds [10, 11, 12, 15, 34, 35]. The
present results show that inhibitors of JNK, p38, and
Erk1/2MAP kinases also downregulate COX-2 expression
and PGE2 production in human chondrocytes which is
likely involved in the mechanisms of their therapeutic ef-
fects in arthritis and other inflammatory diseases.
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